Deubiquitinase <scp>USP9X</scp> loss sensitizes renal cancer cells to <scp>mTOR</scp> inhibition
Juan María Roldán‐Romero(European Bioinformatics Institute), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Javier Lanillos(Spanish National Cancer Research Centre), Pablo Maroto(Hospital de Sant Pau), Sara Mellid(Spanish National Cancer Research Centre), Bruna Calsina(Spanish National Cancer Research Centre), María Monteagudo(Spanish National Cancer Research Centre), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Javier Pardo de Santayana y Coloma(Spanish National Cancer Research Centre), María Santos(Spanish National Cancer Research Centre), Geòrgia Anguera(Hospital de Sant Pau), Cristina Montero‐Conde(Spanish National Cancer Research Centre), Alberto Cascón(Spanish National Cancer Research Centre), Carlos Valdivia, Luis J. Leandro‐García(Spanish National Cancer Research Centre), Ángel M. Martínez‐Montes(Spanish National Cancer Research Centre), Giovanna Roncador(Spanish National Cancer Research Centre)
Cited by 18
Related Papers
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394
<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
|Clinical Cancer Research|2012|330